Forigerimod TFA

• CAT Number: I042396
• Molecular Formula: C117H181N34O32PS.xC2HF3O2
• Purity: ≥95%

Forigerimod TFA (Cat No.: I042396) is the trifluoroacetate salt form of Forigerimod (also known as Lupuzor), a synthetic peptide derived from the spliceosomal protein U1-70K. It acts as an immunomodulator by modulating MHC class II-restricted T-cell responses, promoting immune tolerance without global immunosuppression. Forigerimod is primarily studied for treating systemic lupus erythematosus (SLE), showing promise in reducing disease activity and flares. The TFA salt enhances peptide stability and solubility, making Forigerimod TFA valuable for autoimmune disease research and therapeutic development.

Reference

[1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.
[Content Brief]

[2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701.
[Content Brief]

[3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830-5.
[Content Brief]

[4]. Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018 Jun;90:132-145.
[Content Brief]